Ovarian cancer, version 3.2012.

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA, National Comprehensive Cancer Network
J Natl Compr Canc Netw. 2012 10 (11): 1339-49

PMID: 23138163 · DOI:10.6004/jnccn.2012.0140

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

MeSH Terms (9)

Antineoplastic Combined Chemotherapy Protocols Chemotherapy, Adjuvant Early Detection of Cancer Female Humans Molecular Targeted Therapy Neoadjuvant Therapy Neoplasm Recurrence, Local Ovarian Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities:

Links